Top Page
Island Pharmaceuticals Ltd
(Sydney:ILA)
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Island Pharmaceuticals Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.07K | 118.91K | 1.25M | 11.06K | 0.00 | 0.00 |
| Gross Profit | -729.59K | -1.29M | -1.01M | 11.06K | 0.00 | 0.00 |
| EBITDA | -4.90M | 0.00 | -2.82M | -2.82M | -2.61M | -2.13M |
| Net Income | -7.20M | -3.92M | -2.86M | -2.83M | -2.61M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 8.02M | 7.49M | 2.56M | 2.05M | 4.90M | 6.64M |
| Cash, Cash Equivalents and Short-Term Investments | 6.87M | 7.25M | 1.66M | 2.00M | 4.79M | 6.46M |
| Total Debt | 0.00 | 0.00 | 421.97K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 860.15K | 336.43K | 1.05M | 263.85K | 580.73K | 236.83K |
| Stockholders Equity | 7.16M | 7.16M | 1.52M | 1.79M | 4.32M | 6.40M |
Cash Flow | ||||||
| Free Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Operating Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Investing Cash Flow | -841.70K | 0.00 | 0.00 | 0.00 | 0.00 | 77.37K |
| Financing Cash Flow | 7.41M | 8.36M | 2.79M | -171.36K | 0.00 | 7.30M |
Island Pharmaceuticals Ltd Technical Analysis
Island Pharmaceuticals Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$83.11M | -7.57 | -138.54% | ― | ― | 16.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$66.25M | -5.28 | -49.72% | ― | ― | 10.78% | |
45 Neutral | AU$167.97M | 27.58 | -41.51% | ― | -40.74% | -21.21% | |
43 Neutral | AU$109.06M | -5.66 | -90.37% | ― | ― | 26.38% | |
40 Underperform | AU$38.65M | -10.60 | -159.86% | ― | 110.44% | 35.90% | |
40 Underperform | AU$31.93M | -5.38 | -16.65% | ― | ― | -672.73% |
Island Pharmaceuticals Ltd Corporate Events
Island Pharmaceuticals has requested a trading halt in its shares on the ASX, effective from the start of trading on 2 March 2026. The halt will remain in place until either the commencement of normal trading on 4 March 2026 or the earlier release of a market announcement.
The company says the pause is needed while it finalises an announcement regarding a pending agreement with two strategic U.S. biodefence institutions tied to its Galidesivir program. Management indicated the move is intended to ensure orderly trading and proper disclosure, signalling that a potentially material partnership or collaboration could soon be confirmed.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals Limited reported a sharp increase in its half-year loss for the period ended 31 December 2025, with the loss after tax widening to $4.81 million from $1.53 million a year earlier. Despite the deeper loss, net tangible assets per ordinary security improved to 2.37 cents from 2.14 cents, and the board maintained its stance of not paying or recommending dividends for either the current or prior comparable period.
The company reported no changes in control over entities, no associates or joint ventures, and no dividend reinvestment plan in place, underscoring a relatively straightforward corporate structure during the half-year. The financial statements for the period were reviewed by the company’s auditors, and the half-year report was authorised for release by the board, signalling continued regulatory compliance but also highlighting ongoing losses that shareholders will be monitoring closely.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals has responded to an ASX price query, confirming that recent feedback from the U.S. Food and Drug Administration on the development pathway for its antiviral candidate Galidesivir was materially price-sensitive. The company detailed that it received the FDA correspondence on 30 January 2026, sought expert regulatory advice to interpret the technical guidance, and then requested a trading halt on 2 February 2026 to prevent disorderly trading while preparing a market announcement.
Island explained that only its board and external advisors knew of the FDA feedback initially and that no unusual trading occurred on the day of receipt, supporting its view that continuous disclosure obligations were managed appropriately. It also disclosed that long-standing corporate advisor Ora Capital was briefed on 1 February 2026 to help prepare an investor update, highlighting the procedural scrutiny around how material regulatory information is handled and reinforcing the importance of governance in biotech market disclosures.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals Limited has released an investor-focused presentation outlining its activities in combating urgent viral disease threats and providing an overview of its business and risk profile. The document emphasises that the material is informational only, does not constitute an offer or financial advice, and may be incomplete or subject to change, underscoring that investors must undertake their own due diligence and not rely on the company for guarantees about future performance or outcomes.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals Limited has announced a proposed placement of up to 25,714,285 new fully paid ordinary shares, with an expected issue date of 16 February 2026. The equity raising, to be quoted on the ASX under the company’s existing code ILA, is intended to provide additional capital for the business, underscoring the company’s continued reliance on public market funding to support its pharmaceutical development pipeline and ongoing corporate needs, with potential dilution for existing shareholders depending on final pricing and allocation.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals has raised A$9 million via a placement of 25.7 million new shares at A$0.35 each, cornerstoned by a US-based family office and supported by other local and international investors, extending its cash runway from an existing A$6.87 million position. The funding will fully finance the two-stage Animal Rule development program and New Drug Application for its lead antiviral Galidesivir in Marburg virus, as well as manufacture additional drug supply and progress pre-clinical and regulatory work aimed at broader US Government Strategic National Stockpile opportunities in Ebola and Sudan virus. Management says the capital raise removes a key funding risk just as the FDA has provided clear alignment on Galidesivir’s development pathway, positioning Island to pursue potential US Government procurement and a valuable Priority Review Voucher, which together could unlock significant non-dilutive revenue streams and enhance shareholder value if the program succeeds.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals has secured key guidance from the US Food and Drug Administration validating its proposed animal model for Galidesivir and setting out a two-stage development pathway under the FDA’s Animal Rule, a milestone the company says significantly de-risks the program. The FDA’s alignment on the use of the Angola strain of Marburg virus in cynomolgus macaques allows Island to immediately commence dose-optimisation and pharmacokinetic studies using its first manufactured batch of Galidesivir at Texas Biomedical Research Institute and other potential partners, ahead of a pivotal confirmatory study that could lead to approval, unlock US government stockpile procurement opportunities, and qualify the company for a potentially highly lucrative Priority Review Voucher.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals Ltd has requested and been granted a trading halt on its ordinary shares on the ASX, effective from the start of trading on 2 February 2026, as it prepares to release an announcement related to US FDA feedback on its Galidesivir program. The halt, which is intended to help the company manage its disclosure obligations and maintain an orderly market, will remain in place until either the announcement is released or normal trading resumes on 4 February 2026, signalling that the forthcoming FDA-related update could be material for investors and the company’s development pipeline.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals reported that it is progressing two well-advanced clinical-stage programs targeting infectious diseases, highlighted by the completion of its Phase 2a/b PROTECT clinical trial in dengue. Both assets are positioned for major market potential and may qualify for U.S. Priority Review Vouchers, while recent positive feedback from the FDA on the Animal Rule regulatory pathway and multiple near-term clinical, operational and regulatory catalysts could accelerate development timelines and enhance the company’s strategic value in the antiviral therapeutics space.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals reported a strategically significant December 2025 quarter marked by substantial regulatory and operational progress for its Galidesivir antiviral program. The US FDA confirmed that Galidesivir is eligible for approval under the Animal Rule for use against Marburg virus and would qualify for a Tropical Disease Priority Review Voucher upon such approval, materially de-risking the development pathway and enhancing potential commercial upside. The company deepened its US ecosystem integration by executing a Master Service Agreement with leading BSL-4 facility Texas Biomedical Research Institute for potential non-human primate studies, strengthening its ability to meet Animal Rule requirements, and by bolstering US government engagement through a Washington-based policy advisor and membership in the Medical Countermeasures Coalition. Island also extended its US intellectual property protection for Galidesivir’s COVID-19 use to 2042 and modestly strengthened its balance sheet via option exercises, positioning the company with greater regulatory clarity, IP longevity and operational readiness as it moves toward the next phase of development.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals Limited has notified the market of the issue of 8,000,000 unquoted options, described as options expiring on various dates and at various exercise prices, with an issue date of 12 November 2025. The new options, recorded via an Appendix 3G filing, represent an expansion of the company’s equity-based instruments and may form part of its capital management or incentive arrangements, potentially affecting future dilution and aligning stakeholders with the company’s long-term performance.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.42 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals has reported that the US Food & Drug Administration has requested additional time to finalise its response on the regulatory development pathway for Galidesivir under the Animal Rule, but has not issued any adverse feedback, sought extra data or changed its previously positive stance, including eligibility for Priority Review Voucher status. While awaiting more detailed guidance that will shape planned non-human primate studies in Marburg virus and broader clinical trial plans, the company is continuing study preparations, engagement with US government stakeholders and negotiations with potential study partners, positioning itself to move quickly into the next phase of Galidesivir’s development once the FDA’s program approval and clarifications are received.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.42 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
Island Pharmaceuticals Ltd has secured a Master Service Agreement with Texas Biomedical Research Institute, a leading BSL-4 facility in the USA, to advance the development of its antiviral candidate, Galidesivir. This agreement enables potential non-human primate studies crucial for the FDA’s Animal Rule development pathway, following positive FDA engagement confirming eligibility and potential for a Priority Review Voucher post-approval. The collaboration with Texas Biomed, known for its expertise in high-containment infectious disease research, is a strategic move to progress Galidesivir towards FDA approval, while the company continues to seek additional research partners.
Island Pharmaceuticals Ltd has been granted a US patent for the use of Galidesivir in treating SARS-CoV-2, extending its patent protection until July 2042. This development strengthens Island’s intellectual property portfolio and supports Galidesivir’s potential as a broad-acting antiviral, aligning with the company’s strategy to advance its regulatory pathway for combating the Marburg virus.